Small molecule mGluR1 enhancers based on the lead compound 9H-xanthene-9-carbonyl -carbamicc acid butyl ester derived from random-screening hit diphenylacetyl-carbamic acid ethyl ester were designed and synthesized as useful pharmacological tools for the study of the physiological roles mediated by mGlu1 receptors.
A low molecular weight compound composed of two linked caffeine moieties (Fig. 2d), derived from a screening-based approach, was shown to act as a competitive inhibitor on ChiB1 in the low micromolar (K i = 2.8 ± 0.2 μm) range (Schüttelkopf et al. 2006).
The compounds were derived from in silico screenings using the clinically relevant VEGFR tyrosine kinase inhibitor vatalanib as the lead structure.
Several peptides derived from phage-displayed peptide library screenings have been developed into drug candidates and tested in clinical trials, thus validating their peptide-targeting potential [ 32].
The third type, commonly referred to as off-target interactions (or polypharmacology if this is a designed property), are derived from compound specificities recorded from cross-screening results.
Twenty peptide sets derived from eight different proteins and peptides from peptide library screenings were used to study and determine the ACPA profiles.
These genes derived from the manual revision of 67 publications corresponding to 77 re-sequencing screenings of the whole exomes (49 screenings), the whole genomes (19 screenings) and selected gene sets (9 screenings), conducted on 3640 samples from 23 cancer types (Supplementary Table S1) (17 83).
After a preliminary definition of the assessment framework and total available credits, the priorities of different sub-criteria are derived from sensitivity analyses of a generic building model with screening-based, variance-based and regression methods.
ACPA profiling using microarrays containing 20 peptide sets derived from 8 different proteins and peptides derived from peptide library screenings allowed the identification of 12 distinct ACPA profiles in 374 early arthritis patients.
By exploring, for the first time, the relationship between the GFI and an FI score derived from routine healthcare data, our results contribute to the development of a frailty-screening strategy that meets the needs of primary care providers.
